Innovent Biologics

Home
China
Suzhou
Innovent Biologics

To empower patients worldwide with affordable, high-quality biopharmaceuticals Innovent has launched 11 products in the market.

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. It has 5 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

20/09/2025

We're happy to share that the NMPA has approved a second indication for mazdutide—for glycemic control in adults with type 2 diabetes!

As the world's first dual GCG/GLP-1 receptor agonist approved for T2D, mazdutide provides comprehensive benefits across glycemic control, weight reduction, and hepato-cardio-renal health. This approval expands treatment options for China's 140 million adults living with T2D and supports the vision of Healthy China 2030.

https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-received-approval-from-chinas-nmpa-for-glycemic-control-in-adults-with-type-2-diabetes-302561434.html?tc=eml_cleartime

19/09/2025

Our partner Ollin has completed enrollment in a Phase 1b study of IBI324 (OLN324), a next-generation VEGF/Ang2 bispecific antibody in development for wet AMD and DME, two major causes of vision loss. This study will assess whether IBI324 can offer longer-lasting treatment and stronger disease control, with topline results expected in early 2026. https://www.prnewswire.com/news-releases/innovents-partner-ollin-announces-clinical-updates-on-ibi324-oln324-vegfang-2-302559062.html

17/09/2025

We're excited to present multiple research results at in Paris!

Our findings, including post hoc analyses of Phase 2 and 3 clinical studies of IBI112 (IL-23p19 monoclonal antibody, picankibart), as well as preclinical study results for IBI3013 (IL-15 monoclonal antibody) and IAR129 (IL-4R/OX40L bispecific antibody), will be showcased in seven ePosters.
https://www.prnewswire.com/news-releases/innovent-to-present-multiple-rd-results-of-general-biomedicine-pipeline-at-the-34th-eadv-congress-2025-302556355.html?tc=eml_cleartime

12/09/2025

Innovent has been awarded the MSCI-ESG AAA rating for the second consecutive year, underscoring our ability to sustain excellence in governance, innovation, and responsibility amid a rapidly changing global landscape. By embedding ESG into our corporate DNA, we continue to link scientific innovation with sustainable development for the benefit of patients, partners, and society.

08/09/2025

Innovent announced new data at the 2025 APLAR Congress showing that tigulixostat (IBI128), an investigational xanthine oxidase inhibitor, achieved significantly greater urate-lowering efficacy and favorable safety across all dose groups compared to febuxostat in a Phase 2 study of Chinese gout participants. Building on these positive results, we plan to initiate a Phase 3 clinical study of tigulixostat in China in the second half of 2025. https://www.prnewswire.com/news-releases/innovent-announces-phase-2-results-of-tigulixostat-ibi128-xoi-in-gout-patients-were-published-at-the-27th-asia-pacific-league-of-associations-for-rheumatology-congress-302548517.html?tc=eml_cleartime

05/09/2025

Our CFO, Rachel You, joined Bloomberg TV to discuss Innovent’s 2025 interim results and share insights into our strategy for sustainable growth. She highlighted the strong early performance of mazdutide, our GCG/GLP-1 receptor agonist obesity therapy, and the progress of our expanding pipeline. We invite you to watch the full interview to learn more about what’s ahead for our business and innovation journey.

28/08/2025

Innovent has announced its 2025 interim results, showcasing strong revenue growth, improved profitability, and significant progress under our dual-engine growth model and global innovation strategy. We invite you to read more about how we are expanding our portfolio, advancing next-generation pipelines, and building a solid foundation for sustainable global growth. https://www.prnewswire.com/news-releases/innovent-announces-2025-interim-results-and-business-updates-302539881.html

25/08/2025

We're pleased to share that Innovent has received U.S. FDA clearance to initiate the first global Phase 3 trial of IBI363 (PD-1/IL-2α-bias) in immunotherapy-resistant squamous NSCLC. This milestone advances our first-in-class dual-immune activation therapy into a pivotal, multi-regional trial enrolling roughly 600 patients across the U.S., China, EU, UK, Japan and more. Backed by FDA Fast Track and NMPA Breakthrough Therapy Designations, IBI363 was designed to address critical gaps in care and may help redefine treatment for this difficult-to-treat cancer type.
https://www.prnewswire.com/news-releases/innovent-biologics-announces-us-fda-ind-approval-for-the-first-global-mrct-phase-3-study-marslight-11-of-ibi363-pd-1il-2-bias-in-squamous-non-small-cell-lung-cancer-302537159.html

18/08/2025

Innovent Biologics 2025 Interim Results Conference Call

05/08/2025

We're pleased to share that the U.S. FDA has approved the IND application for IBI3032, Innovent's novel oral GLP-1R agonist, enabling the start of Phase 1 trials in both the U.S. and China. With promising preclinical data and global potential, IBI3032 represents a key milestone in the continued expansion of our CVM pipeline. https://www.prnewswire.com/news-releases/innovent-receives-us-fda-approval-for-ind-application-of-oral-glp-1r-agonist-ibi3032-302520701.html?tc=eml_cleartime

01/08/2025

On World Lung Cancer Day, we recognize the urgent global and national impact of lung cancer, the leading cause of cancer death worldwide, with over 800,000 new cases diagnosed annually in China alone.

At Innovent, we are advancing a broad portfolio of therapies across multiple indications in lung cancer, including TYVYT® (sintilimab) and Byvasda® (bevacizumab), limertinib for EGFR-mutant NSCLC, Dovbleron® for ROS1-positive tumors, IBI363 for patients who have progressed after immunotherapy, and more. We stand with the community in raising awareness, encouraging early detection, and advocating for continued investment in research to bring forward a future with more hope and better care.

28/07/2025

On World Hepatitis Day, we stand with the global call to break down barriers to hepatitis and liver cancer care. At Innovent, we're committed to advancing science and expanding access to innovative therapies to help combat liver cancer and improve outcomes for patients.

Address

Suzhou
215028

Telephone

+8651269566088

Website

https://www.innoventbio.com/

Alerts

Be the first to know and let us send you an email when Innovent Biologics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Innovent Biologics:

Shortcuts

Want your practice to be the top-listed Clinic in Suzhou?